Skip to main content

Drug Interactions between atidarsagene autotemcel and Fluvirin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

influenza virus vaccine, inactivated atidarsagene autotemcel

Applies to: Fluvirin (influenza virus vaccine, inactivated) and atidarsagene autotemcel

GENERALLY AVOID: The administration of inactivated, killed, or otherwise noninfectious vaccines has not been studied in patients receiving autologous hematopoietic stem cell (HSC)-based gene therapy (e.g., atidarsagene autotemcel, elivaldogene autotemcel). In general, patients who undergo myeloablative conditioning followed by autologous HSC-based gene therapy have altered immune competence, which may be associated with a diminished or suboptimal immunologic response to the vaccine. The myeloablative therapy performed prior to HSC transplant (HSCT) is believed to gradually remove immune memory acquired from previous vaccinations, with antibody titers to vaccine-preventable diseases decreasing 1 to 4 years after autologous HSCT if the recipient is not revaccinated.

MANAGEMENT: Vaccination is not recommended in the 6 weeks prior to the start of myeloablative conditioning and until there is demonstrated hematological recovery after the receipt of either atidarsagene autotemcel or elivaldogene autotemcel. Local vaccination guidelines specific to post-autologous HSCT and prescribing information for individual vaccines should be consulted for further guidance. For example, the Advisory Committee on Immunization Practices (ACIP) recommends initiating revaccination with many of these vaccines approximately 6 months after HSCT. The recommendations may differ based on age, immune status, presence of graft-versus-host disease, and specific vaccination being considered.

References

  1. CDC Centers for Disease Control and Prevention (2019) General Best Practice Guidelines for Immunization: Altered Immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf
  2. Department of Health. National Health Service (2019) Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf
  3. (2022) "Product Information. Skysona (elivaldogene autotemcel)." bluebird bio
  4. Public Health Agency of Canada (2023) Immunization of immunocompromised persons: Canadian immunization guide https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-p
  5. Miller PDE, patel sr, Skinner R, et al. (2023) "Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the children's cancer and le" J Infect, 86, p. 1-8
  6. (2024) "Product Information. Lenmeldy (atidarsagene autotemcel)." Orchard Therapeutics
View all 6 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.